MedPath

Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients

Not Applicable
Completed
Conditions
Graves Disease
Interventions
Registration Number
NCT01560299
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Iodine therapy is the best treatment for graves disease.Most patients receive methimozale prior to radio-iodine treatment. This may decrease treatment response to iodine therapy.

Some physicians advice to discontinue methimazole 3 days before radioiodine therapy and others prefer longer off - methimazole period which bothers most patients. This study aimed to evaluate optimum time for methimazole discontinuation in graves disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria
  • age 18-65
  • graves disease(TSH<0.1 &increased FT4 & positive TSI
  • one or more bartlena criteria for radio-iodine therapy
  • 24 hour RAIU>25%
  • euthyroidism after methimazole treatment
Exclusion Criteria
  • pregnancy or lactation
  • moderate or severe graves ophthalmopathy
  • CHF or coronary heart disease
  • palpable thyroid nodule
  • lithium or amiodarone or lugol or ipodate treatment
  • recent imaging with contrast agent
  • very large goiter(more than 150 gram)

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
group oneMethimazoleThis group will be advised to discontinue methimazole 24-48 hour before iodine therapy
group twoMethimazolemethimazole stopped 48-72 hour before radioiodine therapy
group threeMethimazole-
Primary Outcome Measures
NameTimeMethod
thyroid function tests over one year after radioiodine therapymonths 1 , 3 ,6,9,12

thyroid function test may change over one year . In order to consider the patients as cured ,thyroid function tests should reveal hypothyroidism or euthyroidism . In order to rule out temporary hypothyroidism the tests should be repeated after 6 months of radioiodine therapy.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mashad University of Medical Sciences

🇮🇷

Mashad, Khorasan Razavi, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath